Rigel Pharmaceuticals正式宣布，其自主研发的Veppanu™（Vepdegestrant）现已全面上市。这款靶向治疗药物，专门针对ER阳性、HER2阴性且携带ESR1基因突变的晚期或转移性乳腺癌患者。该消息一经发布，便迅速在肿瘤治疗领域引发广泛关注。对于此前内分泌治疗无果或进展的患者而言，这一新药或将带来全新的治疗选择。Rigel通过精准的研发路径，将药物迅速推向临床，意在填补当前治疗领域中的关键空白。
Rigel Pharmaceuticals正式宣布，其自主研发的Veppanu™（Vepdegestrant）现已全面上市。这款靶向治疗药物，专门针对ER阳性、HER2阴性且携带ESR1基因突变的晚期或转移性乳腺癌患者。该消息一经发布，便迅速在肿瘤治疗领域引发广泛关注。对于此前内分泌治疗无果或进展的患者而言，这一新药或将带来全新的治疗选择。Rigel通过精准的研发路径，将药物迅速推向临床，意在填补当前治疗领域中的关键空白。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.